BACKGROUND: HIV may amplify immunological, physiological and functional changes of ageing. We determined associations of frailty phenotype, a T-cell senescence marker (p16(INK4a) expression), age and demographics with exposures of the intracellular metabolites (IM) and endogenous nucleotides (EN) of tenofovir/emtricitabine (TFV/FTC), efavirenz (EFV), atazanavir (ATV) and ritonavir (RTV). METHODS: Plasma and peripheral blood mononuclear cell samples for drug, IM and EN concentrations were collected at four time points in HIV+ adults receiving TFV/FTC with EFV or ATV/RTV. Subjects underwent frailty phenotyping and p16(INK4a) expression analysis. Non-compartmental analysis generated an area under the curve (AUC) for each analyte. Spearman rank correlation and Kruskal-Wallis tests were used to assess associations between AUC, demographics and ageing markers, adjusting for multiple comparisons with the Holm procedure. RESULTS: Subjects (n=79) ranged in age from 22-73 years (median 48 years); 48 were African-American, 24 were female, 54 received EFV. Three subjects (range 51-60 years) demonstrated frailty, with 17 subjects (range 26-60 years) demonstrating pre-frailty. Negative associations were observed between p16(INK4a) expression and each of FTC-triphosphate (r=-0.45), deoxyadenosine triphosphate (dATP; r=-0.47) and deoxycytidine triphosphate (dCTP; r=-0.57) AUCs (P-values <0.02). TFV and FTC AUCs were larger among subjects with lower renal function or higher chronological age (P-values ≤0.05). No associations were observed for EFV, ATV or RTV AUCs. CONCLUSIONS: Associations of IM/EN exposure and p16(INK4a) expression observed here suggest that senescence may alter drug phosphorylation, metabolism or transport. This finding warrants further mechanistic study to ensure optimal treatment in the ageing HIV+ population. Clinicaltrials.gov NCT01180075.
BACKGROUND: HIV may amplify immunological, physiological and functional changes of ageing. We determined associations of frailty phenotype, a T-cell senescence marker (p16(INK4a) expression), age and demographics with exposures of the intracellular metabolites (IM) and endogenous nucleotides (EN) of tenofovir/emtricitabine (TFV/FTC), efavirenz (EFV), atazanavir (ATV) and ritonavir (RTV). METHODS: Plasma and peripheral blood mononuclear cell samples for drug, IM and EN concentrations were collected at four time points in HIV+ adults receiving TFV/FTC with EFV or ATV/RTV. Subjects underwent frailty phenotyping and p16(INK4a) expression analysis. Non-compartmental analysis generated an area under the curve (AUC) for each analyte. Spearman rank correlation and Kruskal-Wallis tests were used to assess associations between AUC, demographics and ageing markers, adjusting for multiple comparisons with the Holm procedure. RESULTS: Subjects (n=79) ranged in age from 22-73 years (median 48 years); 48 were African-American, 24 were female, 54 received EFV. Three subjects (range 51-60 years) demonstrated frailty, with 17 subjects (range 26-60 years) demonstrating pre-frailty. Negative associations were observed between p16(INK4a) expression and each of FTC-triphosphate (r=-0.45), deoxyadenosine triphosphate (dATP; r=-0.47) and deoxycytidine triphosphate (dCTP; r=-0.57) AUCs (P-values <0.02). TFV and FTC AUCs were larger among subjects with lower renal function or higher chronological age (P-values ≤0.05). No associations were observed for EFV, ATV or RTV AUCs. CONCLUSIONS: Associations of IM/EN exposure and p16(INK4a) expression observed here suggest that senescence may alter drug phosphorylation, metabolism or transport. This finding warrants further mechanistic study to ensure optimal treatment in the ageing HIV+ population. Clinicaltrials.gov NCT01180075.
Authors: Naser L Rezk; Richard R Tidwell; Angela D M Kashuba Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-06-15 Impact factor: 3.205
Authors: Cecile D Lahiri; Sijia Tao; Yong Jiang; Anandi N Sheth; Edward P Acosta; Vincent C Marconi; Wendy S Armstrong; Raymond F Schinazi; Aswani Vunnava; Sara Sanford; Ighovwerha Ofotokun Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: J B Dumond; J L Adams; H M A Prince; R L Kendrick; R Wang; S H Jennings; S Malone; N White; C Sykes; A H Corbett; K B Patterson; A Forrest; A D M Kashuba Journal: HIV Med Date: 2013-02-24 Impact factor: 3.180
Authors: Julie B Dumond; Camden P Bay; Julie A E Nelson; Angel Davalos; Andrew Edmonds; Kristina De Paris; Craig Sykes; Kathryn Anastos; Roopali Sharma; Seble Kassaye; Bani Tamraz; Audrey L French; Stephen Gange; Ighovwerha Ofotokun; Margaret A Fischl; David E Vance; Adaora A Adimora Journal: Antimicrob Agents Chemother Date: 2020-08-20 Impact factor: 5.191
Authors: Brian M Maas; Owen Francis; Katie R Mollan; Cynthia Lee; Mackenzie L Cottrell; Heather M A Prince; Craig Sykes; Christine Trezza; Chad Torrice; Nicole White; Stephanie Malone; Michael G Hudgens; Norman E Sharpless; Julie B Dumond Journal: PLoS One Date: 2016-12-30 Impact factor: 3.240
Authors: J B Dumond; J W Collins; M L Cottrell; C R Trezza; Hma Prince; C Sykes; C Torrice; N White; S Malone; R Wang; K B Patterson; N E Sharpless; A Forrest Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-12-26
Authors: J B Dumond; J Chen; M Cottrell; C R Trezza; Hma Prince; C Sykes; C Torrice; N White; S Malone; R Wang; K B Patterson; N E Sharpless; A Forrest Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-12-29